(Q36861097)

16 August 2017

0 references

International workshop on immune tolerance induction: consensus recommendations (English)

1 reference

16 August 2017

0 references

DiMichele DM

1

1 reference

16 August 2017

Hoots WK

2

1 reference

16 August 2017

Pipe SW

3

1 reference

16 August 2017

Rivard GE

4

1 reference

16 August 2017

Santagostino E

5

1 reference

16 August 2017

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

13 Suppl 1

1 reference

16 August 2017

page(s)

1-22

1 reference

New perspectives in hemophilia treatment

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance therapy for haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Inhibitors in haemophilia: clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance: critical issues of factor dose, purity and treatment complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

International immune tolerance registry, 1997 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The international immune tolerance study: a multicenter prospective randomized trial in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Inhibitors: resolving diagnostic and therapeutic dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

High titre inhibitor after continuous factor VIII administration for surgery in a young infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

21 January 2018

Overview of inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Comparison of the international immune tolerance registry and the North American immune tolerance registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Tolerance induction using the Malmö treatment model 1982-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri-Regional Nursing Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance induction in hemophilia A: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Canadian multi-institutional survey of immune tolerance therapy (ITT) -- experience with the use of recombinant factor VIII for ITT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance induction: recombinant vs. human-derived product

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immunoadsorption may provide a cost‐effective approach to management of patients with inhibitors to FVIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The overall effectiveness of prophylaxis in severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Inhibitor antibodies to factor VIII and factor IX: management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Intracranial haemorrhage among a population of haemophilic patients in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Central venous catheter‐related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Consensus recommendations for use of central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Surveillance of infectious complications associated with central venous access devices in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The use of central venous catheters (portacaths) in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Complications of central venous access devices in paediatric haemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The use of the Port-A-Cath in children with haemophilia--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Novel therapies for immune tolerance in haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

The use of rituximab in two children with allo-antibodies towards factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Rituximab in the treatment of high responding inhibitors in severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Rituximab for adolescents with haemophilia and high titre inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immune tolerance in hemophilia and inhibitors: a cost analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Quality of life assessment in clinical practice in haemophilia treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Measuring health state preferences for hemophilia: development of a disease-specific utility instrument

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Factor VIII inhibitors in mild and moderate-severity haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Inhibitors in congenital coagulation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Factor IX inhibitors and anaphylaxis in hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Immunological aspects of inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01497.X

10.1111/J.1365-2516.2007.01497.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference